WR-1065, the active metabolite of amifostine (ethyol®), does not inhibit the cytotoxic effects of a broad range of standard anticancer drugs against human ovarian and breast cancer cells

D. S. Alberts, L. A. Speicher, M. Krutzsch, J. Wymer, R. L. Capizzi, J. Conlon, A. Barrett, M. Aickin

Research output: Contribution to journalArticle

26 Scopus citations

Abstract

Amifostine (WR-2721, Ethyol®), a phosphorylated thiol, demonstrates the unique ability to protect normal but not tumour tissue from cytotoxic damage induced by radiation therapy and chemotherapy. This study tested the effect of amifostine's active metabolite, the free thiol, WR-1065, on the cytotoxicity of standard anticancer drugs against human A2780 ovarian and MCF7 breast cancer cell lines in vitro, using the well-characterised sulphorhodamine B assay. 50% inhibitory concentration (IC50) values were determined for each of 16 different anticancer drugs in the presence and absence of the highest nontoxic dose of WR-1065 from concentration-response curves constructed in triplicate and based on 18 replicate cell culture plates for each tested drug concentration. Pretreatment with WR-1065 had no statistically significant effect on the IC50 value of any of the 16 drugs tested against either the A2780 or MCF7 human tumour cells. These data expand upon previous reports showing that amifostine does not protect tumours from the cytotoxic effects of anticancer agents. The ability of amifostine to protect against dose-limiting toxicity to a variety of normal tissues without protection of tumour should enhance the efficacy ratio of a wide range of standard anticancer drugs.

Original languageEnglish (US)
Pages (from-to)S17-S20
JournalEuropean Journal of Cancer
Volume32
Issue numberSUPPL. 4
DOIs
StatePublished - 1996

Keywords

  • amifostine
  • antineoplastic agents
  • antitumour
  • drug screening assays
  • radiation protective agents

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'WR-1065, the active metabolite of amifostine (ethyol®), does not inhibit the cytotoxic effects of a broad range of standard anticancer drugs against human ovarian and breast cancer cells'. Together they form a unique fingerprint.

  • Cite this